Compare MDA & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDA | INDV |
|---|---|---|
| Founded | 1969 | N/A |
| Country | Canada | United States |
| Employees | 4000 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2026 | 2014 |
| Metric | MDA | INDV |
|---|---|---|
| Price | $31.02 | $37.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | 608.6K | ★ 1.5M |
| Earning Date | 05-07-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $11.03 | N/A |
| P/E Ratio | ★ N/A | $22.82 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $23.23 | $10.91 |
| 52 Week High | $37.45 | $39.33 |
| Indicator | MDA | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 72.47 |
| Support Level | $23.23 | $32.43 |
| Resistance Level | $33.75 | $37.83 |
| Average True Range (ATR) | 1.72 | 1.50 |
| MACD | -0.36 | 0.53 |
| Stochastic Oscillator | 22.54 | 71.67 |
MDA Space Ltd is a developer and manufacturer of technology and services to the space industry. It is an international space mission partner and robotics, satellite systems, and geo-intelligence pioneer. It is engaged in communications satellites, Earth and space observation, space exploration, and infrastructure. The Company collaborates and partners with governments and space agencies, commercial space companies, and defence and aerospace prime contractors in the space industry. Geographically, it generates the majority of its revenue from Canada.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).